Director Dealing – 26th October 2021

e-therapeutics plc

("e-therapeutics" or the "Company")

Director Dealing

Oxford, UK, 26 October 2021 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, announces the following dealing in the Company's ordinary shares of 0.1 pence each ("Ordinary Shares").

Earlier today, Mr Ali Mortazavi, the Company's Chief Executive Officer, purchased 275,000 Ordinary Shares at a price of 36.5 pence each.

Following the transaction, Mr Mortazavi is benefically interested in 50,941,666 Ordinary Shares, representing 9.9% of the Company's total issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Ali Mortazavi
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/	Initial notification
	Amendment
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or
	auction monitor
a)	Name	e-therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
	type of transaction; (iii) each date; and (iv) each place where transactions have been
	conducted
a)	Description of the financial	Ordinary Shares of 0.1 pence
	instrument, type of
	instrument
	Identification code	ISIN: GB00B2823H99
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	275,000 ordinary shares at a price of 36.5 pence per share
d)	Aggregated information	275,000 ordinary shares
	- Aggregated volume	36.5 pence per share
	- Price	Aggregated value: £100,375
e)	Date of the transaction	26 October 2021

f)	Place of the transaction	AIM

Enquiries:
e-therapeutics plc	Tel: [phone]
Ali Mortazavi, CEO	www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-ledin silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.